Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

555
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
555
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

277
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
277
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

435
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
435
Drug Therapy01:28

Drug Therapy

123
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
123
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

451
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
451
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

1.2K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is abnormal brain insulin action implicated in the biology of depression? A pilot neuroimaging study in adolescents.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis.

JAMA psychiatry·2026
Same author

The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients.

Schizophrenia bulletin·2026
Same author

Prevalence of antipsychotic polypharmacy in patients with schizophrenia and other psychotic disorders in the MENAT and EMRO countries: a systematic review and meta-analysis.

Frontiers in psychiatry·2026
Same author

Virtual Reality for the Treatment of Auditory Hallucinations in Schizophrenia Spectrum Disorders: a Systematic Review and Meta-Analysis.

Schizophrenia bulletin·2026
Same author

The Immediate and Sustained Effects of Multi-Session Biparietal Transcranial Direct Current Stimulation on Insight in Schizophrenia.

Schizophrenia bulletin·2026

Related Experiment Video

Updated: Oct 25, 2025

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

18.7K

Schizophrenia: Antipsychotics and drug development.

Gary Remington1, Margaret K Hahn1, Sri Mahavir Agarwal1

  • 1University of Toronto, Department of Psychiatry, University of Toronto, Toronto, Canada; Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.

Behavioural Brain Research
|August 5, 2021
PubMed
Summary

The evolution of antipsychotics from typical to atypical has questioned the utility of these classifications. Future drug development should address schizophrenia

Keywords:
AntipsychoticsAtypicalitySchizophreniaTreatment

More Related Videos

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

3.9K
Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
05:52

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

Published on: November 21, 2013

15.1K

Related Experiment Videos

Last Updated: Oct 25, 2025

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

18.7K
Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

3.9K
Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
05:52

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

Published on: November 21, 2013

15.1K

Area of Science:

  • Neuroscience
  • Psychopharmacology
  • Medical History

Background:

  • Chlorpromazine repositioned schizophrenia as a biological illness, initiating psychopharmacological advancements.
  • The development of antipsychotics evolved from 'typical' to 'atypical' agents.
  • Clozapine's introduction and subsequent research defined 'atypicality' in antipsychotic medication.

Observation:

  • The definition and utility of 'atypical' antipsychotics are increasingly questioned.
  • Antipsychotic drug development has not fully addressed the diverse symptom domains of schizophrenia.
  • Clinical staging and phenotyping reveal significant heterogeneity within schizophrenia.

Findings:

  • The concept of 'atypicality' in antipsychotics may be outdated due to evolving understanding.
  • Current drug development paradigms may not adequately capture schizophrenia's complexity and heterogeneity.
  • A more nuanced approach to drug development is needed, moving beyond a singular 'schizophrenia' target.

Implications:

  • Re-evaluating antipsychotic classification is necessary for future research.
  • Tailoring drug development to specific symptom domains and patient phenotypes is crucial.
  • The paradigm of developing drugs for 'schizophrenia' may need to be abandoned in favor of more precise therapeutic targets.